Mean liver weight (g) (A), liver weight/body ratio (B), hepatic triglyceride (mg/g) (C) and hepatic steatosis quantification (% area) (D) upon completion of the treatment phase. by Elsie D. Oduor (22521785)

Subjects:

Schematic overview of the experimental groups. by Elsie D. Oduor (22521785)

Subjects:

Line graph illustrating mean food intake (in grams) at weekly intervals during the induction phase. by Elsie D. Oduor (22521785)

Subjects:

Mean blood glucose responses (mmol/L) to an oral blood glucose bolus 2g/kg during a 120-minute period and mean area under the curve (mmol/L.min) during the oral blood glucose toler... by Elsie D. Oduor (22521785)

Subjects:

Mean mesenteric, retroperitoneal, pericardial, and total visceral adipose tissue weights (in grams) upon completion of the experiment. by Elsie D. Oduor (22521785)

Subjects:

Line graph illustrating mean body weight (in grams) at weekly intervals during the induction phase. by Elsie D. Oduor (22521785)

Subjects:

Line graph illustrating mean random blood glucose (mmol/L) at weekly intervals during the treatment phase. by Elsie D. Oduor (22521785)

Subjects:

Line graph illustrating mean body weight (in grams) at weekly intervals during the treatment phase. by Elsie D. Oduor (22521785)

Subjects:

Mean lipid profile (mmol/L) upon completion of the experimental period. by Elsie D. Oduor (22521785)

Subjects:

Line graph illustrating mean food intake (g) at weekly intervals during the treatment phase. by Elsie D. Oduor (22521785)

Subjects:

Mean blood glucose responses (mmol/L) to an oral blood glucose bolus 2g/kg during a 120-minute period and mean area under the curve (mmol/L.min) during the oral blood glucose toler... by Elsie D. Oduor (22521785)

Subjects:

Representative liver histology of normal control (A), low-dose Olanzapine (B), negative control (C), test (D), and positive control (E) groups (Hematoxylin and Eosin stain, ×400 ma... by Elsie D. Oduor (22521785)

Subjects:

<i>upd3</i> loss-of-function mutations suppress the synthetic lethal phenotype of <i>Gpdh1</i>^{<i>A10/B18</i>}<i>; Ldh</i>^<i>16/17</i> double mutants. by Madhulika Rai (4352803)

RNAi targeting of <i>upd3</i> expression in muscle of <i>Gpdh1; Ldh</i> double mutant partially suppresses the developmental arrest phenotype. by Madhulika Rai (4352803)

Mst1 knockout or suppressing its kinase activity increases the production of inflammatory mediators by activating the NF-κB pathway. by Jianyang Li (461703)

<i>Gpdh1; Ldh</i> double mutants display increased <i>upd3</i> expression. by Madhulika Rai (4352803)

Immunogenicity results of different vaccination schemes at different time points. by Rima Moghnieh (679199)

Subjects:

Effectiveness of the available COVID-19 primary and booster vaccination schemes against laboratory-confirmed infections during the different waves. by Rima Moghnieh (679199)

Subjects:

Effectiveness of the available COVID-19 primary and booster vaccination schemes against acute-care hospitalization attributed to laboratory-confirmed infections during the differen... by Rima Moghnieh (679199)

Subjects:

Effect of Oxamate, LBP, or their combination on partial glycolysis metabolites in A549 and NCL-H1975 cells after 24 hours of treatment. by Siyu Yuan (7425719)

Subjects: